Development and Complications of Bone Metastases in Men With Prostate Cancer
|
|
- Regina Pope
- 5 years ago
- Views:
Transcription
1 Development and Complications of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences
2 Natural History of Prostate Cancer Progression Many prostate tumors may become castration-resistant and metastasize to bone 1 Castration-Sensitive Castration-Resistant Increased Risk of Fracture and Other Skeletal Complications Death PSA/Tumor Burden Start of ADT Increased Risk for Developing Bone Metastases Bone Metastases ADT: Increased Risk for Bone Loss Time 2
3 Many Men With Castration-Resistant Prostate Cancer (CRPC) Develop Bone Metastases Over 80% of men with CRPC will develop bone metastases 2-5 Nearly half of men with CRPC developed at least one bone metastasis within 2 years 6 Bone metastases commonly cause debilitating bone pain and pathologic fractures 7-9 Once bone metastases develop, median survival is 21.7 months for men with CRPC (n=171) 10 Consider a bone scan to promptly detect bone metastases in men with rising PSA despite ADT 3
4 Identification of Men at Risk for Bone Metastases Is Important In men with prostate cancer and rising PSA despite ADT, the risk of bone metastases is increased with: High absolute PSA levels (>10 ng/ml) Rapidly rising PSA levels or short PSA doubling time Shorter PSA Doubling Time Is Associated With Decreased Bone Metastasis-Free Survival Proportion of Patients With Bone Metastases or Died PSADT <6.3 months PSADT months PSADT >18.8 months PSADT = PSA doubling time Years Since Randomization Assignment 4 A retrospective analysis of 201 patients with nonmetastatic prostate cancer and PSA progression despite ADT showed a statistically significant correlation of baseline PSA levels and increasing PSA velocity with shorter time to bone metastases. Baseline PSA level greater than 10 ng/ml (relative risk, 3.18, 95% CI, ; P<0.001) and PSA velocity (relative risk, 4.34 for each 0.01 increase in PSA velocity; 95% CI, ; P<0.001) independently predicted shorter time to first bone metastasis in the reduced multivariate Cox regression model.
5 Bone Metastases Are Associated With Important Clinical Consequences Consequences of bone metastases in men with prostate cancer: Increased mortality Compared to men without bone metastases, the increased risk for death is: 15 HR=6.6 for men with bone metastases and no skeletal-related events (SREs) HR=10.2 for men with bone metastases plus SREs Debilitating bone pain Patients with bone metastases often experienced debilitating bone pain 16 2 of 3 patients required narcotic pain medication after receiving palliative radiation therapy to bone 17 Fracture and functional impairment Physical and functional impairment was seen in patients who experienced an SRE such as radiation to bone or pathologic fracture 18,19 The average length of stay among men hospitalized for a pathologic fracture was 6.6 days 20 Reduced quality of life A reduced quality of life was reported in men who experienced an SRE such as radiation to bone 19 Increased medical costs Healthcare costs were significantly higher for men with prostate cancer and bone metastases compared with those without bone metastases 21 5
6 The Development of Bone Metastases Depends on Complex Interactions Between Prostate Cancer Cells and the Bone Microenvironment Multiple factors influence interactions between the tumor cells, the seed, and the bone microenvironment, the soil, to promote the development of bone metastases 22,23 1 Prostate cancer cells shed from the primary tumor enter the circulation, and release growth factors, cytokines, and other proteins which promote adhesion and proliferation to the bone 24 Development of Bone Metastases 2 Circulating prostate cancer cells initially adhere to cells lining blood vessels in bone marrow 25 3 Tumor cells are actively recruited to the bone microenvironment by multiple factors and preferentially adhere to areas of increased bone turnover
7 ADT increases bone resorption and subsequently releases multiple factors in the bone microenvironment which may create more fertile conditions for the development of bone metastases in Men With Prostate Cancer 6 Increased bone resorption releases growth factors from the bone matrix, which may further stimulate tumor growth and bone destruction leading to the further development of bone metastases 30,31 4 Tumor cells that have invaded bone secrete multiple factors that stimulate osteoblasts to overproduce growth factors 30,31 5 Increased levels of growth factors drive excessive osteoclast activity and bone resorption resulting in destruction of the bone matrix 30,31 7
8 Development and Complications of Bone Metastases in Men With Prostate Cancer Over 80% of men with CRPC will develop bone metastases which can lead to important clinical consequences, such as debilitating bone pain, fracture, physical and functional impairment, and increased mortality In men with prostate cancer and rising PSA despite ADT, the risk of bone metastases is increased with PSA levels >10 ng/ml, rapidly rising PSA levels or short PSA doubling time The development of bone metastases depends on complex interactions between prostate cancer cells and the bone microenvironment Consider a bone scan to promptly detect bone metastases in men with rising PSA despite ADT 1. Smith MR. Eur Urol Suppl. 2009;8: Scher HI, Morris MJ, Kelly WK, et al. Clin Cancer Res. 2005;11: Tannock IF, de Wit R, Berry WR, et al. N Engl J Med. 2004;351: Petrylak DP, Tangen CM, Hussain MHA, et al. N Engl J Med. 2004;351: Shah RB, Mehra R, Chinnaiyan AM, et al. Cancer Res. 2004;64: Smith MR, Cook R, Lee KA, Nelson JB. Cancer. 2011;117: Yau V, et al. J Pain Symptom Manage. 2004;27: Saad F, et al. Urol Oncol. 2006;24: Saad F, et al. J Natl Cancer Inst. 2004;96: Kantoff PW, et al. N Engl J Med. 2010;363: National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology Prostate Cancer. V Smith MR, Kabbinavar F, Saad F, et al. J Clin Oncol. 2005;23: Petrylak DP. Eur Urol Suppl. 2007;6: Moreira D, Aronson W, Terris M, et al. J Urol. 2010;183(suppl):e335-e Sathiakumar N, et al. Prostate Cancer Prostatic Dis. 2011;14: Gralow J, Tripathy D. J Pain Symptom Manage. 2007;33: Hartsell WF, et al. J Natl Cancer Inst. 2005;97: Coleman RE. Clin Cancer Res. 2006;12(20 suppl):6243s 6249s. 19. Weinfurt KP, Li Y, Castel LD, et al. Ann Oncol. 2005;16: Barlev A, et al. J Manag Care Pharm. 2010;16(9): Schulman KL, Kohles J. Cancer. 2007;109: Chiang AC, Massague J. N Engl J Med. 2008;359: Piris A, Mihm MC. Cancer Treat Res. 2007;135: Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. J Clin Oncol. 2005;23: Fidler IJ. Nat Rev Cancer. 2003;3: Pienta KJ, Loberg R. Clinical Prostate Cancer. 2005;4: Chung LWK, Baseman A, Assikis V, Zhau HE. J Urol. 2005;173: Tantivejkul K, Kalikin LM, Pienta KJ. J Cell Biochem. 2004;91: Logothetis CJ, Lin SH. Nat Rev Cancer. 2005;5: Roodman GD. N Engl J Med. 2004;350: Mundy GR. Nat Rev Cancer. 2002;2: Padalecki SS, Carreon M, Grubbs B, Cui Y, Guise TA. Oncology. 2003;17: Jennbacken K, Tesan T, Wang W, et al. Endocrine-Related Cancer. 2010;17: Lee YC, Cheng CJ, Huang M, et al. J Pathol. 2010;221: Michaelson MD, Marujo RM, Smith MR. Clin Cancer Res. 2004;10: van der Pluijm G, Que I, Sijmons B, et al. Cancer Res. 2005;65: Thalmann GN, Anezinis PE, Chang SM, et al. Cancer Res. 1994;54: Amgen Inc. All rights reserved R1-V1 3/12
Castrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationNon metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationNew Tools for the Urologist in the Management of Patients with Bone Metastases
european urology supplements 6 (2007) 689 694 available at www.sciencedirect.com journal homepage: www.europeanurology.com New Tools for the Urologist in the Management of Patients with Bone Metastases
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationNuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida
Nuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida Dr Pablo Maroto Hospital Sant Pau Dr Pablo Maroto Hospital
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationTiming and Optimization of Radium 223 in CRPC
Timing and Optimization of Radium 223 in CRPC Disclosures Bayer Janssen Objectives Significance of bone metastases Symptoms associated with bone mets Early identification of bone metastases Therapeutic
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationAmgen (Europe) GmbH, Zug, Switzerland, 2 Amgen GmbH, Munich, Germany, 3
Occurrence of skeletal-related events (SRE) in pa9ents with solid tumors (ST): early versus late ini9a9on of SRE preventa9ve agents (SPA) Intorcia M 1, Hohmann D 2, Giannopoulou C 1, Ansorge S 3, Diel
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationThe prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study
Received: 21 September 2017 Accepted: 22 January 2018 DOI: 10.1002/pros.23492 ORIGINAL ARTICLE The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationNIH Public Access Author Manuscript Clin Cancer Res. Author manuscript; available in PMC 2009 June 15.
NIH Public Access Author Manuscript Published in final edited form as: Clin Cancer Res. 2008 June 15; 14(12): 3729 3736. doi:10.1158/1078-0432.ccr-08-0472. Soluble ErbB3 Levels in Bone Marrow and Plasma
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationHHS Public Access Author manuscript Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 September 01.
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: Combined analysis of four phase-2 trials Daniel L. Suzman,
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial
More informationThe Changing Landscape of Treatment Options For Metastatic Castrate-Resistant Prostate Cancer
The Changing Landscape of Treatment Options For Metastatic Castrate-Resistant Prostate Cancer Challenges and Solutions for Physicians and Patients Carole Alison Chr vala, PhD INTRODUCTION Prostate cancer
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationConclusions. Keywords
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer Guru Sonpavde 1, Gregory
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationEfficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone- Resistant Metastatic Prostate Cancer
Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone- Resistant Metastatic Prostate Cancer Hamid Rezvani, Shirin Haghighi, Mojtaba Ghadyani, Hamid Attarian UROLOGICAL ONCOLOGY Taleghani
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationCUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update
Original cua guidelines research CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update Fred Saad, MD, FRCSC; * Sebastien Hotte, MD, FRCSC; Charles Catton, MD,
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationChanges in PSA Kinetics Predict Metastasis- Free Survival in Men with PSA-Recurrent Prostate Cancer Treated With Nonhormonal Agents
Changes in PSA Kinetics Predict Metastasis- Free Survival in Men with PSA-Recurrent Prostate Cancer Treated With Nonhormonal Agents Combined Analysis of 4 Phase II Trials Emmanuel S. Antonarakis, MD; Marianna
More informationKey Words. Biologic markers Breast neoplasms Survival rate Zoledronic acid
The Oncologist Breast Cancer Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity ALLAN LIPTON, a RICHARD J. COOK, b PIERRE MAJOR, c MATTHEW
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationbone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER
bone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER IF YOU VE BEEN DIAGNOSED WITH METASTATIC BREAST CANCER (ALSO KNOWN AS STAGE IV BREAST CANCER),
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationECF chemotherapy for liver metastases due to castration-resistant prostate cancer
Original research ECF chemotherapy for liver metastases due to castration-resistant prostate cancer Shruti Gupta, BHSc; * Kylea Potvin, MD; * D. Scott Ernst, MD; * Frances Whiston; Eric Winquist, MD, MSc,
More informationProstate-specific antigen half-life: a new predictor of progressionfree survival and overall survival in Chinese prostate cancer patients
Original Article Asian Journal of Andrology (2009) 11: 443 450 2009 AJA, SIMM & SJTU All rights reserved 1008-682X/09 $ 32.00 www.nature.com/aja npg 443 : a new predictor of progressionfree survival and
More informationAdvances in the Therapy of Prostate Cancer Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways
EUROPEAN UROLOGY SUPPLEMENTS 8 (2009) 747 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Advances in the Therapy of Prostate Cancer Induced Bone Disease: Current Insights
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationMÉTASTASES OSSEUSES ET RADIUM 223
MÉTASTASES OSSEUSES ET RADIUM 223 Marie-Laure Amram Service d oncologie Hôpitaux Universitaires de Genève Forome du 21.05.2015 Radium-22:3:mécanisme d action Mécanisme d action Mécanisme d action Radium-223
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationMolecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar
Molecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar Seite 1 Bone metastases Different tumors % 80 70 68% 73% 60 50 40 40% 35% 42% 36% 30 20 10 0 5% prostate bladder renal breast thyroid lung GI urological
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationPCa Commentary. Volume 83 September October 2013
1221 Madison Street, First Floor Seattle, WA 98104 P 206-215-2480 ww.seattleprostate.com PCa Commentary Volume 83 September October 2013 Table of Contents Alpharadin, Xofigo Page 1 PTEN gene Page 3 ALPHARADIN
More informationApalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
811450TAU0010.1177/1756287218811450Therapeutic Advances in UrologyVS Koshkin and EJ Small review-article2018 Therapeutic Advances in Urology Review Apalutamide in the treatment of castrate-resistant prostate
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationsilent epidemic,. (WHO),
Tel: 02-740-8686; E-mail: hhbkim@snu.ac.kr silent epidemic,. (WHO),. 5 3, 1. 50 70. 50%, 25%, 20% (12~35%). 2.8% 0.7% 4. ( ). bone remodeling (osteoblast), (osteoclast),.. 3~4.. 70% (osteocyte) (bone lining
More informationSession 5: Isotope therapies and palliative radiotherapy
Session 5: Isotope therapies and palliative radiotherapy Jeffrey Tuan, FRCR Radiation Oncology National Cancer Centre Singapore 15 Dec 2016 Bone metastases SREs are clinically important endpoints The burden
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationIntermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
MOLECULAR AND CLINICAL ONCOLOGY 3: 303-307, 2015 Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer HARUKI KUME, TAKETO KAWAI, MASAYOSHI NAGATA, TAKESHI AZUMA, HIDEYO
More informationBone Health in the Cancer Patient
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Sacred Encounters Perfect Care Healthiest Communities Why
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationAlpha-emitting Radionuclides: Ra-223
Alpha-emitting Radionuclides: Ra-223 prof. dr. K. Goffin Nuclear Medicine and Molecular Imaging Department of Imaging & Pathology UZ Leuven KU Leuven Belgium International Course on Theranostics and Molecular
More information